Carmelo Puliatti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carmelo Puliatti has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Evaldo Favi
General Surgery and Kidney Transplantation Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy
2 shared publications - Mariano Ferraresso
General Surgery and Kidney Transplantation Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy
2 shared publications Ajith James
Nephrology, Royal London Hospital, Barts Health NHS Trust, Whitechapel Rd, London, E1 1BB, UK
1 shared publication- Alessandra Brescacin
General Surgery and Kidney Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
1 shared publication - Carlo Alfieri
Department of Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico , Milan
1 shared publication Chiara Rui
Renal Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza n. 35, 20122, Milan, Italy
1 shared publication
Latest Publications
- Open Access
Allograft Vesicoureteral Reflux after Kidney Transplantation
Allograft vesicoureteral reflux (VUR) is a leading urological complication of kidney transplantation. Despite the relatively high incidence, there is a lack of consensus regarding VUR risk factors, impact on renal function, and management. Dialysis vintage and atrophic bladder have been recognized as the most relevant recipient-related determinants of post-transplant VUR, whilst possible relationships with sex, age, and ureteral implantation technique remain debated. Clinical manifestations vary from an asymptomatic condition to persistent or recurrent urinary tract infections (UTIs). Voiding cystourethrography is widely accepted as the gold standard diagnostic modality, and the reflux is generally graded following the International Reflux Study Committee Scale. Long-term transplant outcomes of recipients with asymptomatic grade I-III VUR are yet to be clarified. On the contrary, available data suggest that symptomatic grade IV-V VUR may lead to progressive allograft dysfunction and premature transplant loss. Therapeutic options include watchful waiting, prolonged antibiotic suppression, sub-mucosal endoscopic injection of dextranomer/hyaluronic acid copolymer at the site of the ureteral anastomosis, and surgery. Indication for specific treatments depends on recipient’s characteristics (age, frailty, compliance with antibiotics), renal function (serum creatinine concentration < 2.5 vs. ≥ 2.5 mg/dL), severity of UTIs, and VUR grading (grade I-III vs. IV-V). Current evidence supporting surgical referral over more conservative strategies is weak. Therefore, a tailored approach should be preferred. Properly designed studies, with adequate sample size and follow-up, are warranted to clarify those unresolved issues.
Open AccessAllograft Vesicoureteral Reflux after Kidney Transplantation
Allograft vesicoureteral reflux (VUR) is a leading urological complication of kidney transplantation. Despite the relatively high incidence, there is a lack of consensus regarding VUR risk factors, impact on renal function, and management. Dialysis vintage and atrophic bladder have been recognized as the most relevant recipient-related determinants of post-transplant VUR, whilst possible relationships with sex, age, and ureteral implantation technique remain debated. Clinical manifestations vary from an asymptomatic condition to persistent or recurrent urinary tract infections (UTIs). Voiding cystourethrography is widely accepted as the gold standard diagnostic modality, and the reflux is generally graded following the International Reflux Study Committee Scale. Long-term transplant outcomes of recipients with asymptomatic grade I-III VUR are yet to be clarified. On the contrary, available data suggest that symptomatic grade IV-V VUR may lead to progressive allograft dysfunction and premature transplant loss. Therapeutic options include watchful waiting, prolonged antibiotic suppression, sub-mucosal endoscopic injection of dextranomer/hyaluronic acid copolymer at the site of the ureteral anastomosis, and surgery. Indication for specific treatments depends on recipient’s characteristics (age, frailty, compliance with antibiotics), renal function (serum creatinine concentration < 2.5 vs. ≥ 2.5 mg/dL), severity of UTIs, and VUR grading (grade I-III vs. IV-V). Current evidence supporting surgical referral over more conservative strategies is weak. Therefore, a tailored approach should be preferred. Properly designed studies, with adequate sample size and follow-up, are warranted to clarify those unresolved issues.
- 25 November 2019
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 24 (4) , 356-368
Utility and safety of early allograft biopsy in adult deceased donor kidney transplant recipients
Delayed graft function (DGF) is considered a risk factor for rejection after kidney transplantation (KTx). Clinical guidelines recommend weekly allograft biopsy until DGF resolves. However, who may benefit the most from such an aggressive policy and when histology should be evaluated remain debated.
- 25 November 2019
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 24 (4) , 356-368
Utility and safety of early allograft biopsy in adult deceased donor kidney transplant recipients
Delayed graft function (DGF) is considered a risk factor for rejection after kidney transplantation (KTx). Clinical guidelines recommend weekly allograft biopsy until DGF resolves. However, who may benefit the most from such an aggressive policy and when histology should be evaluated remain debated.
- 1 April 2004
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (3) , 475-478
Living kidney transplantation: a starting experience
- 1 April 2004
- Published by Elsevier in Transplantation Proceedings
- Vol. 36 (3) , 475-478
Living kidney transplantation: a starting experience
- 1 April 2001
- Published by Wiley in Artificial Organs
- Vol. 25 (4) , 273-280
Efficacy of Nonwoven Fabric Bioreactor Immobilized with Porcine Hepatocytes for Ex Vivo Xenogeneic Perfusion Treatment of Liver Failure in Dogs
- 1 April 2001
- Published by Wiley in Artificial Organs
- Vol. 25 (4) , 273-280
Efficacy of Nonwoven Fabric Bioreactor Immobilized with Porcine Hepatocytes for Ex Vivo Xenogeneic Perfusion Treatment of Liver Failure in Dogs